Calendar
event
Ex dividend date
26 Jun 2025
event_available
Last Dividend Payment
01 Jan 1970
About PharmaSGP Holding SE
Ticker
info
PSG
Trading on
info
XETRA
ISIN
info
DE000A2P4LJ5
Industry
info
-
Sector
info
-
CEO
info
Peter Gerckens
Headquarters
info
Lochhamer Schlag 1, Gräfelfing, undefined, Germany, 82166
Employees
info
91
Website
info
https://pharmasgp.com
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve pain), headaches, and migraines; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness, and mood swings; Deruba, a cream for skin redness; Lentisol that prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. The company sells its products through pharmacies and wholesalers. It also exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.
Metrics
BasicAdvanced
Market cap
info
€334M
P/E ratio
info
17.26
EPS
info
€1.68
Dividend Yield
info
1.76%
Beta
info
-0.03
Forward P/E ratio
info
8.48
EBIDTA
info
€36.9M
Ex dividend date
info
2025-06-26
Price & volume
Market cap
info
€334M
Average daily volume
info
-
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
€0.51
Dividend yield
info
1.76%
Forward dividend per share
info
€0.05
Forward dividend yield
info
0.17%
Payout ratio
info
3.50%
Valuation
P/E ratio
info
17.26
Forward P/E
info
8.48
PEG ratio
info
-
Trailing P/E
info
17.26
Price to sales
info
2.73
Price to book
info
9.11
Earnings
EPS
info
€1.68
EPS estimate (current quarter)
info
€0.00
EPS estimate (next quarter)
info
€0.00
EBITDA
info
€36.9M
Revenues (TTM)
info
€122M
Revenues per share (TTM)
info
€10.38
Technicals
Beta
info
-0.03
52-week High
info
€30.00
52-week Low
info
€22.58
50-day moving average
info
€28.52
200-day moving average
info
€26.10
Short ratio
info
0
Short %
info
0.00%
Management effectiveness
ROE (TTM)
info
48.46%
ROA (TTM)
info
13.58%
Profit margin
info
16.14%
Gross profit margin
info
€111M
Operating margin
info
20.42%
Growth
Quarterly earnings growth (YoY)
info
7.90%
Quarterly revenue growth (YoY)
info
10.80%
Share stats
Outstanding Shares
info
11.5M
Float
info
0.6M
Insiders %
info
91.33%
Institutions %
info
1.69%
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
€0.34
€0.41
-16.24%
Q2 • 24Missed
€0.47
€0.47
-
Q3 • 24Beat
€0.48
€0.47
2.13%
Q4 • 24Beat
€0.48
€0.47
2.13%
Q1 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
€30.3M
€5.5M
18.13%
Q4 • 24
€33.5M
€4.7M
14.13%
Q1 • 25
10.60%
-13.76%
-22.03%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
€114M
€82.3M
72.03%
Q4 • 24
€118M
€81.5M
68.97%
Q1 • 25
3.41%
-0.97%
-4.24%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
€4M
€-0.1M
€-15.1M
€3.8M
Q4 • 24
€4.2M
€-0.7M
€-0.7M
€3.5M
Q1 • 25
6.61%
388.28%
-95.48%
-7.88%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a PharmaSGP Holding SE share?
Collapse

PharmaSGP Holding SE shares are currently traded for undefined per share.

How many shares does PharmaSGP Holding SE have?
Collapse

PharmaSGP Holding SE currently has 11.5M shares.

Does PharmaSGP Holding SE pay dividends?
Collapse

Yes, PharmaSGP Holding SE does pay dividends.

What is PharmaSGP Holding SE 52 week high?
Collapse

PharmaSGP Holding SE 52 week high is €30.00.

What is PharmaSGP Holding SE 52 week low?
Collapse

PharmaSGP Holding SE 52 week low is €22.58.

What is the 200-day moving average of PharmaSGP Holding SE?
Collapse

PharmaSGP Holding SE 200-day moving average is €26.10.

Who is PharmaSGP Holding SE CEO?
Collapse

The CEO of PharmaSGP Holding SE is Peter Gerckens.

How many employees PharmaSGP Holding SE has?
Collapse

PharmaSGP Holding SE has 91 employees.

What is the market cap of PharmaSGP Holding SE?
Collapse

The market cap of PharmaSGP Holding SE is €334M.

What is the P/E of PharmaSGP Holding SE?
Collapse

The current P/E of PharmaSGP Holding SE is 17.26.

What is the EPS of PharmaSGP Holding SE?
Collapse

The EPS of PharmaSGP Holding SE is €1.68.

What is the PEG Ratio of PharmaSGP Holding SE?
Collapse

The PEG Ratio of PharmaSGP Holding SE is null.